Teva to Close 11 More Manufacturing Facilities in 2019
The drugmaker published its fourth quarter and annual reports Wednesday, dropping almost 8% on NYSE after forecasting a steep cut in profits for 2019
Teva Pharmaceutical Industries has let go over 10,000 employees since launching its reorganization plan in December 2017 and closed seven manufacturing facilities—with 11 more slated for closure or divestment in 2019, according to a Wednesday earnings call with CEO Kåre Schultz.
For daily updates, subscribe to our newsletter by clicking here.Teva published its fourth quarter and annual reports Wednesday, closing 7.79% down on NYSE after missing on the analyst consensus for its non-GAAP earnings per share for both the quarter and the year, and forecasting 2019 revenues to be much lower than analyst expectations.
Teva CEO Kåre Schultz. Photo: PR
The company’s reorganization, which also includes portfolio streamlining, is intended to help the company meet its significant debt covenants (which now stand at $27.1 billion) and manage the continuous erosion of its profit from multiple sclerosis drug Copaxone following the launch of generic competition in both the U.S. and Europe in late 2017.
- Teva to Sell Northern Israeli Facility to Private Equity Fund FIMI
- Teva Signs Deal to Sell Closed Israeli Factory
- CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports
The company expects to see the global sales of the drug—which provided a fifth of Teva’s total revenues in 2016— fall from $2.4 billion in 2018 to only around $1.5 billion in 2019. At the end of 2018 Teva still had around a 75% market share, Schultz said, but that is expected to go down.
“This is the year where we bottom out on revenue and operating profit,” Schultz said, adding that Teva expects to return to growth in 2020 and “continue to do so in the coming years, based on the launches of the new products.“